

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Andersen et al.

Serial No.: 09/757,788

Group Art Unit: 1614

Filed: January 10, 2001

Examiner: To be assigned

Confirmation No: 8259

For: Transepithelial Delivery of GLP-Derivatives

**PETITION AND FEE FOR EXTENSION OF TIME (37 C.F.R. 1.136(a))**

Commissioner for Patents  
Washington, DC 20231

Sir:


It is respectfully requested that the time for response to the Notice to Comply with Sequence Rules dated December 6, 2001 be extended for a period of 1 month from February 6, 2002 to March 6, 2002. Applicant(s) hereby petition(s) for such extension of time.

In the event that an additional extension of time is required, Applicant(s) hereby petition(s) for such extension of time. The Commissioner of Patents is authorized to charge the required fee, if applicable, to Deposit Account No. 14-1447.

Please charge the required fee, estimated to be \$110, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: February 28, 2002

  
Richard W. Bork, Reg. No. 36,459  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123



23650

PATENT TRADEMARK OFFICE

